BioWorld Asia

Dec. 10, 2003

Actelion, Merck Enter Oral Renin Inhibitor Pact Worth Up To $272M

Swiss biopharmaceutical firm Actelion Ltd. added $10 million to its cash pile, on the strength of an exclusive alliance with Merck & Co. Inc. in the area of oral renin inhibitors. (BioWorld International) Read More

Europe Fumbles Two Major Biotech-Related Decisions

'Reverse Vaccination' Might Help Stop Unwanted Immune Response

Clinical Trials Could Become More Difficult For Small Firms

PPL On The Block; Dolly's Creator Fades Into History

Cyclacel In-Licenses Cancer Compound From Sankyo Co.

Bavarian Nordic Investing In Production Facility, R&D

Stockholm Planning Bioscience Hub; Funding Concerns Remain

French Food Safety Agency Has Bt11 Sweet Corn Doubts

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 10, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...